Skip to main content
. 2015 Oct 6;31(3):309–321. doi: 10.1093/mutage/gev070

Figure 3.

Figure 3.

BMD10 analysis of in vitro MN dose responses in human lymphocytes albendazole (green) flubendazole (black), R-reduced flubendazole (dark blue), S-reduced flubendazole (light blue) and albendazole sulfoxide (red), in human lymphocytes. The top figure shows that the four parameter (m5-bv) exponential model provided a suitable fit to each dose response using the compound as covariate for BMD analysis. The dotted lines show the BMD10 derivations for each dose response, and these correspond to the mid-point for each line plotted in the bottom figure. These lines in the bottom graph span the BMDL10 to the BMDU10 derived from the top figure using PROAST v50.8. Albendazole and flubendazole were equipotent, and the R- and S-metabolites of flubendazole were less potent and of similar potency to albendazole sulfoxide. Hydrolysed flubendazole showed no dose response using BMD analysis and was omitted from this covariate analysis.